Abstracts Archive - Page 472 of 1683 - ATC Abstracts

2020 American Transplant Congress
Challenging Dogma That Anti-Thymocyte Globulin Induction with Delayed Calcineurin Inhibitor Benefits Patients with Renal Insufficiency Undergoing Heart Transplant
M. Kittleson, J. Patel, D. Chang, E. Kransdorf, D. Geft, K. Nishihara, A. Shen, A. Velleca, L. Czer, F. Esmailian, J. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Anti-thymocyte globulin (ATG) induction is used in approximately 50% of heart transplant (HTx) patients in the United States to induce tolerance. Other programs only…
2020 American Transplant Congress
Outcomes of Hiv-Positive Patients Post-Cardiac Transplantation
G. S. Liu¹, A. M. Wolfson², A. D. Salimbangon³, R. R. Chand⁴, P. Banankhah¹, J. Nattiv¹, P. A. Genyk¹, P. A. Kingsford¹, J. P. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, E. C. DePasquale¹, A. S. Vaidya¹
¹Keck Medicine of USC, Los Angeles, CA, ²University of Arizona Sarver Heart Center, Tucson, AZ, ³UCLA Medical Center, Los Angeles, CA, ⁴Harbor-UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth-Israel Medical Center, Newark, NJ
*Purpose: Human immunodeficiency virus (HIV) infection is no longer an absolute contraindication to heart transplantation (HT) in many HT centers, but long-term post-HT outcomes of…
2020 American Transplant Congress
Comparison of Outcomes between Patients Bridged to Heart Transplantation with ECMO versus Those Not Bridged with ECMO During the Years 1985 to 2019
D. J. Miklin¹, A. D. Salimbangon², G. S. Liu¹, P. Banankhah¹, P. A. Genyk¹, P. Kingsford¹, R. R. Chand³, J. P. Li¹, D. Vucicevic⁴, A. S. Vaidya¹, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, A. Kiankhooy¹, J. Nattiv¹, S. Hashmi¹, S. Nuno¹, J. Pizula¹, A. E. Lee¹, K. Yang¹, S. Shaw¹, E. DePasquale¹, W. M. Aaron⁵
¹LAC-USC, Los Angeles, CA, ²UCLA Medical Center, Los Angeles, CA, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴Newark Beth-Israel Medical Center, Newark, NJ, ⁵University of Arizona Sarver Heart Center, Tucson, AZ
*Purpose: Some patients with cardiogenic shock require extracorporeal membrane oxygenation (ECMO) for successful bridging to heart transplantation (HT). Herein, we report on the outcomes and…
2020 American Transplant Congress
Viremic Hepatitis C (HCV) Donors a Viable Option for Lung Transplant Recipients Treated with Real World Delayed Therapy
S. A. Kakoullis, E. M. Eichenberger, J. M. Steinbrink, E. Maziarz, H. Ali, H. Berry, J. Haney, J. Klapper, J. M. Reynolds, C. R. Wolfe
Duke University, Durham, NC
*Purpose: We present an IRB-approved trial of nucleic acid test (NAT) positive HCV donors (D+) used for HCV-negative recipients (R-) at Duke University for patients…
2020 American Transplant Congress
Evaluation of the Discrimination of 13 Mortality Risk Scores after Heart Transplantation in a Contemporary UNOS Cohort
G. Coutance, J. Patel, E. Kransdorf, R. Levine, E. Passano, J. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Multiple pre-transplant scores aimed at stratifying the risk of death or allograft loss after heart transplantation have been developed over time but their use…
2020 American Transplant Congress
Outcomes and Health Care Utilization after Early Hospital Dismissal in Kidney Transplantation: An Analysis of 1001 Consecutive Cases
E. Calderon¹, Y. Chang², J. M. Chang¹, C. Velazco¹, E. Giorgakis¹, A. A. Moss¹, H. Khamash³, R. Heilman³, K. S. Reddy¹, A. K. Mathur¹
¹Transplant Surgery, Mayo Clinic, Phoenix, AZ, ²Kern Center for the Science of Health Care Delivery, Mayo Clinic, Phoenix, AZ, ³Department of Nephrology, Mayo Clinic, Phoenix, AZ
*Purpose: Perioperative care after kidney transplantation has improved with reduction in length of operative stay to as low as two days, but this has an…
2020 American Transplant Congress
Willingness to Accept and Beliefs Regarding Organs from HIV-Infected Donors: A Multi-Center Survey of Transplant Candidates Living with HIV
S. Rasmussen¹, S. Seaman¹, M. Bowring¹, D. Brown¹, A. Massie¹, A. Tobian¹, M. Henderson¹, F. Fletcher², B. Smith², A. Chao³, N. Gorupati³, K. Prakash⁴, S. Aslam⁴, D. Lee⁵, S. Trinh⁶, V. Kirchner⁷, T. Pruett⁷, G. Haidar⁸, K. Hughes⁸, M. Malinis⁹, D. Segev¹, J. Sugarman¹, C. Durand¹
¹JHU, Baltimore, MD, ²UAB, Birmingham, AL, ³UCSF, San Francisco, CA, ⁴UCSD, San Diego, CA, ⁵Drexel, Philadelphia, PA, ⁶Ochsner, New Orleans, LA, ⁷UMN, Minneapolis, MN, ⁸UPMC, Pittsburgh, PA, ⁹Yale, New Haven, CT
*Purpose: HIV-infected (HIV+) donor to HIV+ recipient (HIV D+/R+) transplantation might improve access to transplantation for candidates living with HIV. However, it is unclear whether…
2020 American Transplant Congress
Belatacept-Based Regimens: Induction and Recipient Gender Influence Outcomes
N. Wilson¹, A. R. Shields², A. Wiseman³, A. L. Christianson¹, S. Tremblay¹, D. Kaufman⁴, J. P. Leone⁵, A. J. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Colorado, Denver, CO, ⁴U Wisconsin, Madison, WI, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷U Illinois Chicago, Chicago, IL
*Purpose: Renal function and adverse event profiles in kidney transplant (KTx) patients under belatacept (BELA) based immunosuppression are significantly improved over calcineurin inhibitors, however BELA…
2020 American Transplant Congress
Incident Malignancies among Post Kidney-Transplant Patients by Type of Induction Immunosuppression and by Age
L. Wang, J. Motter, S. Bae, D. Segev, M. McAdams DeMarco
Johns Hopkins University, Baltimore, MD
*Purpose: Adult kidney-transplant (KT) recipients have a differential risk of malignancies based on their induction immunosuppression (IS) therapy. However, older recipients are more likely to…
2020 American Transplant Congress
Lost to Follow-Up in Kidney Transplant Recipients – A QI Project
M. R. D'Costa, H. S. Ohl, S. Iyengar, K. C. Kolbet, C. L. Williams, K. A. Larson, M. S. Ward, H. M. Shriver, W. K. Kremers, M. El Ters
Mayo Clinic, Rochester, MN
*Purpose: Our center actively follows kidney transplant recipients (KTRs) from across the USA and many other countries for the life of the allograft with recommended…